Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
R935788 (Fostamatinib disodium)
Cat No.
CEI-0266
Description
R935788 (Fostamatinib disodium) can potently inhibit syk with IC50 of 41 nM.
CAS No.
1025687-58-4
Molecular Weight
624.42
Purity
>99%
Storage
2 years at -20centigrade Powder
Targets
syk
Molecular Formula
C23H24FN6O9P.2Na
Chemical Name
2H-Pyrido[3,2-b]-1,4-oxazin-3(4H)-one, 6-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-2,2-dimethyl-4-[(phosphonooxy)methyl]-, sodium salt (1:2)
Solubility
DMSO 0.4 mg/mL Water
In vitro
As a prodrug of the spleen tyrosine kinase (Syk) inhibitor R406, fostamatinib can potently inhibit SYK with IC50 of 41 nM. As Syk is a key mediator of Fc and B-cell receptor signaling in inflammatory cells (B-cells, mast cells, macrophages and neutrophils), fostamatinib can significantly reduce major inflammatory mediators such as TNF-alpha, IL-1, IL-6 and IL-18, leading to reduced inflammation and bone degradation in models of RA.
In vivo
Fostamatinib can also inhibit antigen-dependent B-cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL). R788 effectively inhibits BCR signaling in vivo, resulting in reduced proliferation and survival of the malignant B cells and significantly prolonged survival of the treated animals. The growth-inhibitory effect of R788 occurs despite the relatively modest cytotoxic effect in vitro and is independent of basal Syk activity, suggesting that R788 functions primarily by inhibiting antigen-dependent BCR signals. In a phase II clinical trial, fostamatinib treatment effectively improved American College of Rheumatology response rates in patients with RA.
Download
Download Datasheet